Navigation Links
The Launch of Three New Parkinson's Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics
Date:7/30/2013

BURLINGTON, Mass., July 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of key current brands and the launch of three new therapies will help sustain the Parkinson's disease (PD) market throughout the 2012-2022 forecast period, despite growing competition from generics. As a result of these competing forces, total sales of therapies used to treat PD will remain relatively flat over the next decade, beginning at $2.3 billion in 2012 and ending at $2.4 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Parkinson's Disease finds that dopamine agonists will maintain the largest class-level market share through 2022 at approximately 30 percent. For the drug-class leaders pramipexole (Boehringer Ingelheim's Mirapex, other brands, generics; Mirapex ER, other brands) and ropinirole (GlaxoSmithKline's Requip, generics; GlaxoSmithKline/SkyePharma's Requip XL, other brands, generics), growing reliance on convenient once-daily formulations is expected to render the original, three-times-daily formulations nearly obsolete by the second half of the 2012-2022 forecast period. Similarly, the use of the once-daily, transdermal product rotigotine (UCB/Otsuka Pharmaceutical's Neupro, other brands) will continue to grow within the class, primarily outside of Europe, following its 2012 U.S. market re-entry and 2013 launch in Japan.

The findings also reveal that the launch of three emerging therapies through 2015 will provide useful treatment alternatives in PD. Impax Laboratories' Rytary, a reformulation of levodopa (multiple brands, generics), is expected to be prescribed, at least initially, in more-advanced patients experiencing periods of "off" time but will compete with established levodopa-adjunct therapies including the catechol-O-methyltransferase inhibitor entacapone (Novartis/Orion Pharma's Comtan/Stalevo, other brands, generics). Third-to-market monoamine oxidase-B inhibitor safinamide (Newron Pharmaceuticals/Zambon Pharma/Meiji Seika Pharma) has proved effective both in early PD and as an adjunct to levodopa in more advanced patients but will contend with the class leader rasagiline (Teva/Lundbeck's Azilect). Lastly, Acadia Pharmaceuticals' inverse agonist of 5-HT2A receptors pimavanserin is poised to become the first therapy approved specifically to treat psychotic symptoms associated with PD (a key comorbidity), but will likely compete with current antipsychotic agents that are used off-label with some clinical success today. All three of these emerging agents will face intensifying competition from generic alternatives within their respective market segments.

"The late-stage PD therapy pipeline is populated with a range of symptomatic agents targeting niche populations, but, as such, these products may have more-restricted commercial potential," said Decision Resources Senior Business Insights Analyst Nadja Rozovsky, Ph.D. "Delaying disease progression remains the greatest unmet need in the treatment of PD, but it is one that is still far from realization."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Using Success & Failure Roadmap Paves the Way for Positive New Product Launches in Oncology
2. Indegene builds on Aptilon acquisition to launch new iMCM framework for enhanced Enterprise-wide Multichannel Marketing (MCM) deployment.
3. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
4. ProteinSimple Launches Multimode Imager with IR Capability
5. Primal Pictures Launches Functional Anatomy for Movement & Injuries (FAMI) App Series for Health and Fitness Professionals
6. Glenmark Pharmaceuticals Announces Launch of its Child Health CSR Programme in Kenya
7. Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
8. A*STARs SIMTech and NUS Faculty of Engineering Launch Joint Labs to Boost Manufacturing Productivity
9. Educating Key Stakeholder to Support a Successful Diabetes Product Launch
10. Products From Eight Health-IT Vendors First to Receive Certification Under New Program Launched by IHE USA and ICSA Labs
11. HORIBA Scientific Launches New Raman ParticleFinder Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):